newsNirsevimab has the potential to offer RSV protection for all…
3 March 2022 | By European Pharmaceutical Review
Nirsevimab has the potential to offer RSV protection for all infants, with a single dose showing 74.5 percent efficacy in the Melody Phase III trial.